Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks
在Zacks上打开
Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say

Alcon (ALC) reported $2.72 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 4.9%. EPS of $0.91 for the same period compares to $0.79 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $2.73 billion, representing a surprise of -0.6%. The company delivered an EPS surprise of +2.25%, with the consensus EPS estimate being $0.89.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales and other revenues- Net Sales: $2.72 billion compared to the $2.73 billion average estimate based on three analysts. The reported number represents a change of +4.9% year over year. Net Sales- Total Surgical: $1.48 billion compared to the $1.49 billion average estimate based on three analysts. The reported number represents a change of +4.2% year over year. Net Sales- Total Vision care: $1.24 billion versus the three-analyst average estimate of $1.25 billion. The reported number represents a year-over-year change of +5.8%. Net Sales- Total Surgical- Consumables: $789 million versus $777.63 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change. Net Sales and other revenues- Other revenues: $20 million versus the three-analyst average estimate of $23.15 million. The reported number represents a year-over-year change of -20%. Net Sales- Total Vision Care- Contact lenses: $737 million versus $741.37 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change. Net Sales- Total Vision Care- Ocular health: $500 million versus the three-analyst average estimate of $505.09 million. The reported number represents a year-over-year change of +8.2%. Net Sales- Total Surgical- Implantables: $422 million compared to the $435 million average estimate based on three analysts. The reported number represents a change of -2.3% year over year. Net Sales- Total Surgical- Equipment/other: $269 million versus $273.4 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.7% change.

View all Key Company Metrics for Alcon here>>>

Shares of Alcon have returned +16.8% over the past month versus the Zacks S&P 500 composite's -3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Alcon (ALC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research